Alcohol-Associated Liver Disease¶
Chapter 353 | Part 10: Disorders of the Gastrointestinal System
KEY CLINICAL POINTS¶
- Alcohol-associated liver disease (ALD) encompasses a spectrum from fatty liver to cirrhosis, with acute-on-chronic hepatitis being a severe form.
- 7% of U.S. adults meet unhealthy drinking criteria ( ≥ 2 drinks/day for women, ≥ 3 for men), with the pandemic increasing ALD morbidity/mortality.
- Diagnosis requires exclusion of other liver diseases in heavy drinkers, using imaging (ultrasound/MRI/CT) and liver biopsy when needed.
1. DEFINITION & OVERVIEW¶
Alcohol-associated liver diseases (ALD) comprise a spectrum of disorders linked to chronic alcohol consumption, ranging from non-alcoholic fatty liver disease (NAFLD) to cirrhosis. Acute alcohol-associated hepatitis (AAH) is an acute-on-chronic form of ALD with high mortality.
Table 353-1: Factors for Progression of Alcohol-Associated Liver Disease¶
| Factor | Description |
|---|---|
| Alcohol amount/duration | Key driver of disease progression |
| Drinking pattern | Binge drinking/excessive consumption outside meals increases risk |
| Genetic factors | PNPLA3 polymorphism (rs73590047) is a major risk factor |
| Female sex | Women develop ALD at lower alcohol intake |
| Smoking | Independent risk factor for cirrhosis |
| MASLD | Obesity/metabolic dysfunction synergistically worsens ALD |
| Chronic liver diseases | Viral hepatitis/hemochromatosis exacerbate ALD |
1.1 Spectrum of ALD¶
ALD includes: 1) Alcohol-associated fatty liver (most common, reversible with abstinence), 2) Alcohol-associated steatohepatitis (NASH-like), 3) Fibrosis/cirrhosis, and 4) Acute-on-chronic hepatitis (AAH).
1.2 Pathophysiology¶
Ethanol metabolism via ADH1 and CYP2E1 generates acetaldehyde, causing oxidative stress, lipid peroxidation, and DNA damage. Epigenetic changes increase lipogenesis while suppressing fatty acid oxidation.
2. EPIDEMIOLOGY¶
ALD is a leading cause of liver disease globally. The U.S. has 4.7% prevalence of alcohol-associated fatty liver (1.5% with ≥ F2 fibrosis). Alcohol-related cirrhosis is the 11th leading cause of death, causing 1.16 million annual deaths (48% attributable to alcohol).
Table 353-2: Symptoms and Signs of ALD¶
| System | Findings |
|---|---|
| General | Tiredness, malnutrition, sarcopenia |
| Abdominal | Abdominal discomfort, hepatomegaly, splenomegaly, ascites, caput medusae |
| Cutaneous | Spider angioma, palmar erythema, jaundice |
| Neurologic | Peripheral neuropathy, hepatic encephalopathy (asterixis), Wernicke-Korsakoff syndrome |
| Cardiovascular | Edema, rhinophyma |
| Reproductive | Gynecomastia, gonadal atrophy, amenorrhea |
2.1 Demographics¶
Women develop ALD at lower alcohol intake than men. Heavy episodic drinking ( ≥ 4 drinks/women, ≥ 5/men per occasion) is a key risk factor.
2.2 Mortality¶
Liver cirrhosis is the 11th leading cause of mortality globally. 48% of cirrhosis cases are alcohol-related. AAH has 30% 3-month mortality in severe cases.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Ethanol metabolism generates acetaldehyde and reactive oxygen species (ROS), causing lipid peroxidation, DNA damage, and mitochondrial dysfunction. Epigenetic changes increase lipogenesis while suppressing fatty acid oxidation. Gut microbiome dysbiosis and increased intestinal permeability contribute to systemic inflammation.
Table 353-3: Laboratory Findings in ALD¶
| Parameter | Findings |
|---|---|
| AST/ALT ratio | >1 (especially >2) |
| AST levels | Rarely >300 IU/L in steatosis; >400 IU/L in hepatitis |
| Bilirubin/INR | Normal in steatosis; elevated in cirrhosis/hepatitis |
| Albumin/platelets | Low in cirrhosis |
| MELD score | ‡20 indicates severe disease |
3.1 Metabolic Pathways¶
Ethanol → Acetaldehyde (via ADH1/CYP2E1) → Acetate (via ALDH). Inherited ALDH2 deficiency causes acetaldehyde accumulation in Asians.
3.2 Oxidative Stress¶
ROS generation from acetaldehyde metabolism leads to lipid peroxidation, DNA damage, and mitochondrial dysfunction. This contributes to hepatic steatosis and fibrosis.
4. CLINICAL FEATURES¶
ALD is often asymptomatic until decompensation. Acute-on-chronic hepatitis presents with rapid jaundice (bilirubin >3 mg/dL), fever, and systemic inflammatory response syndrome (SIRS). Cirrhosis presents with ascites, varices, and hepatic encephalopathy.
5. DIFFERENTIAL DIAGNOSIS¶
Exclude viral hepatitis, Wilson’s disease, autoimmune liver disease, drug-induced liver injury (DILI), and ischemic hepatitis. Confirm with liver biopsy and imaging.
5.1 Confounding Factors¶
Ischemic hepatitis (hypotension, bleeding, sepsis), DILI, autoimmune hepatitis, and uncertain alcohol use (AST <50 or >400 IU/L, AST/ALT <1.5).
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis requires exclusion of other liver diseases. Use ultrasound/MRI/CT for imaging, liver stiffness measurement (FibroScan), and liver biopsy when needed. Confirm with transjugular biopsy if confounding factors are present.
Table 353-4: Diagnostic Criteria for Alcohol-Associated Hepatitis¶
| Criteria | Description |
|---|---|
| Clinical diagnosis | Alcohol use + liver dysfunction + exclusion of other causes |
| Maddrey Discriminant Function (MDF) | 4.6 × (PT prolongation) + bilirubin ‡32 indicates severe disease |
| MELD score | ‡20 indicates severe disease |
6.1 Diagnostic Tools¶
CAP ultrasound, MR-PDFF for fat quantification. FibroScan (liver stiffness <6 kPa = normal, >12.5 kPa = cirrhosis). Fib-4 score (<3.25 excludes advanced fibrosis).
6.2 Laboratory Tests¶
AST/ALT ratio >1, elevated bilirubin/INR in cirrhosis. MELD score for prognosis ( ≥ 20 indicates severe disease).
7. MANAGEMENT & TREATMENT¶
Prolonged abstinence is the cornerstone. Glucocorticoids (prednisolone 40 mg/d or methylprednisolone 32 mg IV) are used for severe AAH (MDF ≥ 32 or MELD >20). Liver transplantation is indicated for end-stage disease.
Table 353-5: Treatment of Alcohol-Associated Hepatitis¶
| Therapy | Indication | Duration |
|---|---|---|
| Glucocorticoids | Severe AH (MDF ‡32 or MELD >20) | 28 days |
| Liver transplantation | Non-responders or contraindications | Early referral |
| Nutrition | All patients | 35–40 kcal/kg + vitamins |
7.1 Treatment Algorithm¶
Figure 353-1: Confirm diagnosis with TJ biopsy if needed. Moderate disease (MDF <32/MELD ≤ 20): 28 days of prednisolone. Severe disease: glucocorticoids + albumin. Transplant for non-responders or contraindications.
7.2 Supportive Care¶
Enteral nutrition (35–40 kcal/kg), micronutrient/vitamin supplementation, and IV albumin for volume expansion. Monitor for hepatic encephalopathy and variceal bleeding.
8. PROGNOSIS & COMPLICATIONS¶
Mortality is 20% for moderate AH and ~30% for severe AH. Complications include hepatic encephalopathy, ascites, variceal bleeding, hepatorenal syndrome, and HCC. Cirrhosis increases risk of liver failure and mortality.
8.1 Prognostic Scores¶
Maddrey Discriminant Function (MDF), MELD, and ABIC scores predict short-term mortality. Child-Pugh-Turcotte (CPT) and MELD scores assess long-term prognosis.
9. SPECIAL CONSIDERATIONS¶
Pregnancy: Fetal alcohol syndrome risk. Pediatrics: ALD in children with chronic alcohol exposure. Elderly: Increased risk of hepatic decompensation. Contraindications for glucocorticoids include sepsis, AKI, and multiorgan failure.
10. KEY POINTS & CLINICAL PEARLS¶
- Prolonged abstinence is the only proven therapy for ALD reversal.
- MDF ≥ 32 or MELD >20 indicates severe AH requiring glucocorticoids.
- Liver transplantation is the definitive treatment for end-stage ALD.
- Exclude other liver diseases in heavy drinkers using imaging and biopsy.
- Nutritional support is critical for all ALD patients.